paper-with-me

Papers

In silico clinical trials in drug development: a systematic review

2025-03-11 · Bohua Chen, Lucia Chantal Schneider, Christian Roever, Emmanuelle Comets, Markus Christian Elze, Andrew Hooker, Joanna IntHout, Anne-Sophie Jannot, Daria Julkowska, Yanis Mimouni, Marina Savelieva, Nigel Stallard, Moreno Ursino, Marc Vandemeulebroecke, Sebastian Weber, Martin Posch, Sarah Zohar, Tim Friede

In the context of clinical research, computational models have received increasing attention over the past decades. In this systematic review, we aimed to provide an overview of the role of so-called in silico clinical trials (ISCTs) in medical applications. Exemplary for the broad field of clinical medicine, we focused on in silico (IS) methods applied in drug development, sometimes also referred to as model informed drug development (MIDD). We searched PubMed and ClinicalTrials.gov for published articles and registered clinical trials related to ISCTs. We identified 202 articles and 48 trials, and of these, 76 articles and 19 trials were directly linked to drug development. We extracted information from all 202 articles and 48 clinical trials and conducted a more detailed review of the methods used in the 76 articles that are connected to drug development. Regarding application, most articles and trials focused on cancer and imaging related research while rare and pediatric diseases were only addressed in 18 and 4 studies, respectively. While some models were informed combining mechanistic knowledge with clinical or preclinical (in-vivo or in-vitro) data, the majority of models were fully data-driven, illustrating that clinical data is a crucial part in the process of generating synthetic data in ISCTs. Regarding reproducibility, a more detailed analysis revealed that only 24% (18 out of 76) of the articles provided an open-source implementation of the applied models, and in only 20% of the articles the generated synthetic data were publicly available. Despite the widely raised interest, we also found that it is still uncommon for ISCTs to be part of a registered clinical trial and their application is restricted to specific diseases leaving potential benefits of ISCTs not fully exploited.

📄 PDF Abstract BibTeX arXiv:2503.08746

Code (0)

등록된 구현이 없습니다.

Tasks

Articles

Methods 이 논문이 사용한 방법론

Softmax The Softmax output function transforms a previous layer's output into a vector of probabilities. It is commonly used for multiclass classification. Given an input vector $x$…
Attention 설명 없음

Similar Papers 제목 키워드 기반

Artificial Intelligence for In Silico Clinical Trials: A Review

2022-09-16 · Zifeng Wang, Chufan Gao, Lucas M. Glass, Jimeng Sun

A clinical trial is an essential step in drug development, which is often costly and time-consuming. In silico trials are clinical trials conducted digitally through simulation and modeling as an alternative to tradition…

Decoding Drug Discovery: Exploring A-to-Z In silico Methods for Beginners

2024-12-15 · Hezha O. Rasul, Dlzar D. Ghafour, Bakhtyar K. Aziz, Bryar A. Hassan 외

The drug development process is a critical challenge in the pharmaceutical industry due to its time-consuming nature and the need to discover new drug potentials to address various ailments. The initial step in drug deve…

Drug DesignDrug Discovery

DeepCRE: Transforming Drug R&D via AI-Driven Cross-drug Response Evaluation

2024-03-06 · Ting Zhang, Hao Zhou, Hainan Wu, Hanwen Sunchu 외

The fields of therapeutic application and drug research and development (R&D) both face substantial challenges, i.e., the therapeutic domain calls for more treatment alternatives, while numerous promising pre-clinical dr…

From Bench to Bedside: A Review of Clinical Trials in Drug Discovery and Development

2024-12-12 · Tianyang Wang, Ming Liu, Benji Peng, Xinyuan Song 외

Clinical trials are an indispensable part of the drug development process, bridging the gap between basic research and clinical application. During the development of new drugs, clinical trials are used not only to evalu…

Drug DiscoveryMarketing

Generation of Drug-Induced Cardiac Reactions towards Virtual Clinical Trials

2025-02-11 · Qian Shao, Bang Du, Zepeng Li, Qiyuan Chen 외

Clinical trials remain critical in cardiac drug development but face high failure rates due to efficacy limitations and safety risks, incurring substantial costs. In-silico trial methodologies, particularly generative mo…